OverviewSuggest Edit

Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. It develops programs across distinct molecular targets and biologic pathways modulating both the immune system and the tumor.

TypePublic
Founded2016
HQBoston, MA, US
Websiteikenaoncology.com

Latest Updates

Employees (est.) (Jul 2021)50(+52%)
Share Price (Sept 2021)$12.8(-1%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Ikena Oncology

Mark Manfredi

Mark Manfredi

President and Chief Executive Officer
Douglas R. Carlson

Douglas R. Carlson

Chief Operating Officer & EVP, Finance
Jeffrey Ecsedy

Jeffrey Ecsedy

Chief Scientific Officer
Sergio Santillana

Sergio Santillana

Chief Medical Officer
Maude Tessier

Maude Tessier

Chief Business Officer
Alfredo Castro

Alfredo Castro

Senior Vice President, Discovery
Show more

Ikena Oncology Office Locations

Ikena Oncology has an office in Boston
Boston, MA, US (HQ)
645 Summer St #101
Show all (1)

Ikena Oncology Financials and Metrics

Ikena Oncology Revenue

USD

Revenue (Q2, 2021)

3.5m

Net income (Q2, 2021)

(12.7m)

EBIT (Q2, 2021)

(12.7m)

Market capitalization (23-Sept-2021)

465.8m

Closing stock price (23-Sept-2021)

12.8

Cash (30-Jun-2021)

264.0m

EV

209.4m
Ikena Oncology's current market capitalization is $465.8 m.
USDQ1, 2021Q2, 2021

Revenue

3.5m3.5m

General and administrative expense

3.2m4.9m

R&D expense

10.0m11.4m

Operating expense total

13.2m16.2m
USDQ1, 2021Q2, 2021

Cash

281.0m264.0m

Prepaid Expenses

2.2m4.7m

Current Assets

283.2m268.7m

PP&E

2.1m2.1m
USDQ1, 2021Q2, 2021

Net Income

(9.7m)(22.4m)

Depreciation and Amortization

89.0k234.0k

Accounts Payable

48.0k452.0k

Cash From Operating Activities

(13.2m)(28.9m)
USDQ1, 2021

Revenue/Employee

101.4k

Financial Leverage

1.3 x
Show all financial metrics

Ikena Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Ikena Oncology Online and Social Media Presence

Embed Graph

Ikena Oncology News and Updates

Ikena Oncology to Participate in September 2021 Virtual Investor Conferences

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced that management will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Co…

Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that Dr. Mark Manfredi, CEO of Ikena Oncology, will participate…

Ikena Oncology Blogs

Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs

Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs Content Import Thu, 08/12/2021 - 07:01 Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs August 12, 2021 at 7:01 AM EDT …

Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference

BOSTON --(BUSINESS WIRE)--May 26, 2021-- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that management will participate in a fireside chat at the 2021

Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021

Closed IPO and Raised $144 Million in Gross Proceeds to Fund Targeted Oncology Therapies IND Submissions for Lead Targeted Oncology Program, IK-930, and BMS-partnered program, IK-412, Remain on Track for Second Half of 2021 BOSTON --(BUSINESS WIRE)--May 13, 2021-- Ikena Oncology, Inc.

Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors

BOSTON --(BUSINESS WIRE)--Apr. 15, 2021-- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the appointment of Maria Koehler , M.D., Ph.D.

Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

BOSTON --(BUSINESS WIRE)--Mar. 30, 2021-- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the closing of its initial public offering of

Ikena Oncology Announces Pricing of Initial Public Offering

BOSTON --(BUSINESS WIRE)--Mar. 25, 2021-- Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares

Ikena Oncology Frequently Asked Questions

  • When was Ikena Oncology founded?

    Ikena Oncology was founded in 2016.

  • Who are Ikena Oncology key executives?

    Ikena Oncology's key executives are Mark Manfredi, Douglas R. Carlson and Jeffrey Ecsedy.

  • How many employees does Ikena Oncology have?

    Ikena Oncology has 50 employees.

  • Who are Ikena Oncology competitors?

    Competitors of Ikena Oncology include SystImmune, WindMIL Therapeutics and Century Therapeutics.

  • Where is Ikena Oncology headquarters?

    Ikena Oncology headquarters is located at 645 Summer St #101, Boston.

  • Where are Ikena Oncology offices?

    Ikena Oncology has an office in Boston.

  • How many offices does Ikena Oncology have?

    Ikena Oncology has 1 office.